Yes. Mass General Brigham Health Plan (formerly AllWays Health Partners; rebranded January 2023) covers Spravato (esketamine) for treatment-resistant depression in Massachusetts when prior authorization criteria are met. Two recent changes worth knowing: as of May 1, 2025, MGB Commercial added Spravato monotherapy as an option for TRD — meaning a concurrent oral antidepressant is no longer required. And as of January 1, 2026, MGB Commercial Spravato moved from the medical benefit to the pharmacy/specialty benefit, changing which contact channel you'll use.
Across Lumin Health's 2026 commercial Spravato (esketamine) authorizations: 100% approval rate, with a median 4-day decision turnaround. Lumin Health's pre-submission medical-necessity review and standardized clinical documentation packet contribute to this outcome. Individual approval depends on plan-specific PA criteria — see Mass General Brigham Health Plan's policy summary below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
Mass General Brigham Health Plan covers Spravato for adults with treatment-resistant major depressive disorder when all of the following are documented (per MGB Commercial/Exchange Pharmacy Benefit policy effective January 1, 2026):
For MGB members on the MassHealth UPPL Medical Benefit policy (effective September 1, 2024): the same antidepressant trial structure applies, with the additional requirement of at least 4 weeks of therapy per trial, and combination with an oral antidepressant is still required. MassHealth uniquely permits ‘reauthorization by physician will infer a positive response to therapy’ wording at reauthorization — an unusually permissive standard.
Initial authorization (TRD): 3 months. Reauthorization: 12 months with documented improvement in depressive symptoms. MDD-with-acute-suicidal-ideation pathway: 1-month initial; recertification beyond 1 month requires meeting the TRD initial criteria.
Quantity/site: Spravato is designated specialty and (effective 1/1/2026 for Commercial) is filled through a contracted specialty pharmacy, not buy-and-bill at the medical benefit. REMS-certified site required; at least 2 hours of post-administration monitoring per FDA REMS.
Two Massachusetts statutes are particularly relevant when a commercial insurer reviews a Spravato prior authorization:
The “deemed granted” rule. Under 211 CMR 52.07, a Massachusetts commercial carrier that fails to respond to a complete prior authorization request within two business days is deemed to have granted the authorization. This applies to all major Massachusetts commercial carriers — Aetna, Blue Cross Blue Shield of Massachusetts, Cigna, Harvard Pilgrim Health Care, Mass General Brigham Health Plan, UnitedHealthcare, and the Group Insurance Commission's contracted carriers.
External review through the Office of Patient Protection. If your commercial insurer denies a Spravato authorization, you have the right to request external review by the Health Policy Commission's Office of Patient Protection (OPP). The filing window is four months from the final internal denial; OPP issues decisions within 45 days. Historically, more than 40% of OPP external reviews resolve in the patient's favor — an unusually patient-favorable rate compared with most states' insurance-department-administered review processes.
Lumin Health's Massachusetts locations (Newton, Cambridge, Woburn, Brookline) coordinate Spravato authorizations directly with Mass General Brigham Health Plan. Because of the 1/1/2026 benefit shift to pharmacy/specialty, our PA team uses MGB's Pharmacy Benefit channel as the primary route for Commercial members:
Spravato treatment at Lumin Health is available at all four Massachusetts locations: Newton, Cambridge, Woburn, and Brookline. All Lumin Health Spravato locations are REMS-certified per FDA requirements.
How MGB Health Plan compares with other major Massachusetts commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes. MGB Commercial requires PA per the Commercial/Exchange Pharmacy Benefit policy effective January 1, 2026. The criteria require a major depressive disorder diagnosis, age 18+, mental-health-specialist prescriber (psychiatrist, psychiatric NP, or psychiatric PA), inadequate response to two prior antidepressants (one SSRI plus one non-SSRI), and inadequate response or contraindication to one augmentation strategy (SGA/lithium/second AD/thyroid hormone). Spravato may be used as monotherapy or with an oral antidepressant for TRD as of 5/1/2025.
As of January 1, 2026, MGB Commercial Spravato moved from the medical benefit to the pharmacy/specialty benefit. Before this date, Commercial claims went through the medical-benefit channel (phone 833-895-2611 / fax 888-656-6671). After this date, Commercial submissions go through MGB's Pharmacy Benefit line (phone 800-711-4555 / fax 844-403-1029) and the medication is dispensed through a contracted specialty pharmacy. Note: the published policy PDF still lists both contact channels in the header, but the 10/08/2025 review history confirms the medical benefit no longer applies as of 1/1/2026 for Commercial.
Not for Commercial members as of May 1, 2025. MGB updated its TRD criteria at February 2025 P&T to reflect updated FDA package labeling, and Spravato monotherapy is now permitted for TRD on MGB Commercial. The MGB MassHealth UPPL Medical Benefit policy (effective 9/1/2024) still requires combination with an oral antidepressant. The MDD-with-acute-suicidal-ideation pathway also still requires combination with an oral antidepressant.
Yes. MGB's policy explicitly recognizes psychiatric nurse practitioners and psychiatric physician assistants as qualifying mental-health specialists for the prescriber requirement. Many other commercial payers limit prescribing to MD/DO psychiatrists, so this is a meaningful access advantage on MGB Health Plan.
For TRD, the initial authorization is 3 months, with reauthorization granted in 12-month increments when documented improvement in depressive symptoms is provided. For MDD with acute suicidal ideation or behavior, the initial authorization is 1 month; recertification beyond 1 month requires the member to meet the TRD initial criteria (two failed AD classes plus an augmentation failure or contraindication).
Step 1 — File a Level 1 internal appeal. Deadline: Per Massachusetts state mandate (M.G.L. c.176O), Massachusetts commercial members have 180 days from the date of service or claim denial to file an internal appeal with their carrier. Verify the exact deadline in your MGB Health Plan Member Handbook (Appendix C/D, Member Appeals section) — MGB's commercial member-facing appeal deadline was not retrievable verbatim from the public site at the time this page was published. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Mass General Brigham Health Plan, Appeals Department, 399 Revolution Drive, Suite 850, Somerville, MA 02145. Phone: 1-800-462-5449 (Member Services). For Spravato-specific PA submission/appeal contacts: Commercial Pharmacy Benefit 800-711-4555 (fax 844-403-1029) or MassHealth Specialty 877-519-1908 (fax 855-540-3693). Provider portal: massgeneralbrighamhealthplan.org/providers/authorization-guidelines.
Step 2 — Peer-to-peer (P2P) review. MGB Health Plan offers peer-to-peer review at the precertification stage through their Pharmacy Benefit utilization review team. Your prescriber contacts the MGB clinical reviewer named in the denial letter to request a P2P.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), MGB Health Plan must resolve urgent internal appeals within 72 hours. Request by calling 1-800-462-5449 and documenting medical urgency with your prescriber.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. MGB Health Plan (formerly AllWays Health Partners) historically uses Optum / United Behavioral Health as its behavioral-health vendor on certain commercial products. Confirm the BH-vendor structure on your specific plan summary. As of January 1, 2026, MGB Commercial Spravato moved from the medical benefit to the pharmacy/specialty-pharmacy benefit, which may also change the appeal lane. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Mass General Brigham Health Plan medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: Per Massachusetts state mandate (M.G.L. c.176O), Massachusetts commercial members have 180 days from the date of service or claim denial to file an internal appeal with their carrier. Verify the exact deadline in your MGB Health Plan Member Handbook (Appendix C/D, Member Appeals section) — MGB's commercial member-facing appeal deadline was not retrievable verbatim from the public site at the time this page was published. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Mass General Brigham Health Plan, Appeals Department, 399 Revolution Drive, Suite 850, Somerville, MA 02145. Phone: 1-800-462-5449 (Member Services). For Spravato-specific PA submission/appeal contacts: Commercial Pharmacy Benefit 800-711-4555 (fax 844-403-1029) or MassHealth Specialty 877-519-1908 (fax 855-540-3693). Provider portal: massgeneralbrighamhealthplan.org/providers/authorization-guidelines.
Step 2 — Peer-to-peer (P2P) review. MGB Health Plan offers peer-to-peer review at the precertification stage through their Pharmacy Benefit utilization review team. Your prescriber contacts the MGB clinical reviewer named in the denial letter to request a P2P.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), MGB Health Plan must resolve urgent internal appeals within 72 hours. Request by calling 1-800-462-5449 and documenting medical urgency with your prescriber.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. MGB Health Plan (formerly AllWays Health Partners) historically uses Optum / United Behavioral Health as its behavioral-health vendor on certain commercial products. Confirm the BH-vendor structure on your specific plan summary. As of January 1, 2026, MGB Commercial Spravato moved from the medical benefit to the pharmacy/specialty-pharmacy benefit, which may also change the appeal lane. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Mass General Brigham Health Plan medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
